Page 129 - Haematologica-5

Relapses in AIDS-related lymphomas
given. Only 37.0% of patients received their full planned course of therapy.
Patients who experienced treatment delays and/or dose reductions or received a reduced number of chemotherapy cycles were significantly older (42 vs. 45 years; P=0.042) and had received the GMALL-protocol significantly more often than patients who completed the full planned course of therapy (P=<0.001) (Online Supplementary Table S3). Overall, 86.2% of patients with CD20+ lymphomas
received rituximab. There was no difference in the relapse rate between patients with or without administration of rituximab (P=0.75), and our results remained consistent when patients without rituximab were excluded (data not shown).
Factors influencing the RFS
To investigate the influence of different factors, includ- ing treatment reduction or delay on 5yRFS, we investigat-
Table 2. Risk factors for 5-year relapse-free survival (including all aggressive non-Hodgkin lymphoma in first complete remission; n=254). Aggressive
NHL (N=254)
5-year relapse-free P survival % (univariate)
Male (n=230) 87
Female (n=24) 96 0.229
>60Y (n=24) 77
<60Y (n=228) 89 0.178 Yes (n=17) 82
No (n=204) 90 0.305 Yes (n=47) 81
No (n=193) 90 0.101 Yes (n=44) 86
No (n=137) 88 0.637 Yes (n=37) 86
No (n=202) 88 0.573 Yes (n=56) 87
No (n=193) 88 0797
Low (n=100) 95
Intermediate (n=104) 84
High (n=34) 82 0.039 I/II (n=93) 95
III/IV (n=156) 83 0.005
Yes (n=71) 87
No (n=181) 88 0.936 0-1 (n=159) 89
2-5 (n=78) 86 0.635
Yes (n=146) 86
No (n=96) 92 0.143 Viral load b.d. (n=74) 88
Naive (n=134) 88
Therapy failure (n=39) 87 0.986
Yes (n=234) 89
No (n=9) 67 0.033 Positive (n=213) 88
Negative (n=24) 87 0.888
DLBCL (n=127) 88
BL (n=91) 89
PBL (n=29) 89
ARL, not further classifiable (n=7) 57 0.064
CHOP (n=163) 84
GMALL (n=87) 95 0.013
P
(multivariate)
Sex
Age
CNS involvement
BM involvement
Bulky Disease
CD4+ T cells <50x109/l
Prior AIDS-defining illness
IPI score
Ann Arbor stage
Extranodal involvement
ECOG score
Elevated LDH
Antiretroviral Treatment
cART during Chemotherapy
CD20 positive lymphoma
Lymphoma subtype
Chemotherapy
Indicator
0.760
0.853 0.011
0.026
Indicator
0.072
0.703 0.034
0.005
Univariate statistics:Log rank test.Multivariate statistics:Cox regression.Viral load b.d.:Viral load below limit of detection;cART:combination antiretroviral therapy;BL:Burkitt lymphoma; DLBCL: diffuse large B-cell lymphoma; PBL: plasmablastic lymphoma; IPI: International Prognostic Index; BM: bone marrow; CNS: central nervous system; ECOG: Eastern Cooperative Oncology Group scale.
haematologica | 2018; 103(5)
861